Capital Law is delighted to have advised PulmonIR on an investment from IP Group, Finance Wales and the Swansea University Innovation Fund.

Groundbreaking research by Professor Paul Lewis from Swansea University’s Medical School into Chronic Obstructive Pulmonary Disease led to the development of a new technology that can quickly diagnose and monitor this condition. PulmonIR was formed to secure the venture capital required for the development of the technology and the relevant clinical trials. Clinical trials in collaboration with Cwm Taf University Health Board to validate the technology are underway, being the next step on the road to launching a commercial product on to international healthcare markets.

Dr Mark Bowman, Chief Executive Officer, PulmonIR Ltd said: “As founders, Paul and I were very impressed with Capital Law’s handling of our investment completion. We worked closely with Laura Herdman to close the deal over a short period of time. Laura was very professional and highly diligent throughout the process. In particular, she always took time to carefully explain the complicated issues that arose during what could have been a highly stressful period.”

Laura Herdman from Capital Law said: “It was a pleasure to work with Mark and his team on this investment, which could revolutionise the way in which pulmonary disease is diagnosed and treated. The involvement of three high profile investors in this start-up reflects just how much potential there is in the technology. We wish PulmonIR every success.”

For more information, please contact Laura Herdman.